CTOs on the Move

Myrexis

www.myrexis.com

 
Myrexis, Inc. is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.myrexis.com
  • 305 Chipeta Way
    Salt Lake City, UT USA 84108
  • Phone: 801.214.7800

Executives

Name Title Contact Details

Similar Companies

Promosome

Promosome is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exothera

Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium

Atreca

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.

Redpin Therapeutics

Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.